Trade

with

Immunogen Inc
(NASDAQ: IMGN)
AdChoices
8.75
-0.47
-5.10%
After Hours :
8.75
0.00
0.00%

Open

8.80

Previous Close

9.22

Volume (Avg)

1.74M (1.02M)

Day's Range

8.70-9.66

52Wk Range

7.70-18.19

Market Cap.

792.07M

Dividend Rate ( Yield )

-

Beta

2.08

Shares Outstanding

85.91M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 59.90M

    • Net Income

    • -71.36M

    • Market Cap.

    • 792.07M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -119.15

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.08

    • Forward P/E

    • -12.39

    • Price/Sales

    • 12.48

    • Price/Book Value

    • 9.93

    • Price/Cash flow

    • -14.08

      • EBITDA

      • -66.93M

      • Return on Capital %

      • -37.67

      • Return on Equity %

      • -72.25

      • Return on Assets %

      • -37.67

      • Book Value/Share

      • 0.88

      • Shares Outstanding

      • 85.91M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 15.00

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -0.70

        • Cashflow Estimate

        • -0.65

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 49.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 16.44

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -119.15

            • 39.38

            • Net Profit Margin

            • -119.15

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -288.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -287.90

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.09

              • 2.92

              • Quick Ratio

              • 6.85

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 2.18

              • 2.21

              • Book Value/Share

              • 0.88

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -10.59

                • 217.39

                • P/E Ratio 5-Year High

                • -24.26

                • 634.30

                • P/E Ratio 5-Year Low

                • -5.94

                • 124.82

                • Price/Sales Ratio

                • 12.61

                • 9.52

                • Price/Book Value

                • 10.03

                • 8.61

                • Price/Cash Flow Ratio

                • -14.08

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -72.25

                        (-63.40)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -37.67

                        (-37.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -72.25

                        (-63.40)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.32

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -71.53M
                      Operating Margin
                      -119.43
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -14.08
                      Ownership

                      Institutional Ownership

                      91.53%

                      Top 10 Institutions

                      67.39%

                      Mutual Fund Ownership

                      54.93%

                      Float

                      70.77%

                      5% / Insider Ownership

                      0.92%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • PrimeCap Odyssey Growth Fund

                      •  

                        5,855,100

                      • 0.00

                      • 6.82

                      • Fidelity® Growth Company Fund

                      •  

                        5,087,920

                      • -10.17

                      • 5.92

                      • PrimeCap Odyssey Aggressive Growth Fund

                      •  

                        3,769,817

                      • -0.67

                      • 4.39

                      • Bb Biotech AG

                      •  

                        3,165,816

                      • 0.00

                      • 3.68

                      • Pictet-Biotech

                      •  

                        2,378,761

                      • 4.76

                      • 2.73

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,586,457

                      • 0.00

                      • 1.85

                      • Legg Mason ClearBridge US Aggressive Gr

                      •  

                        1,509,290

                      • 0.00

                      • 1.76

                      • Vanguard Small Cap Index

                      •  

                        1,491,294

                      • -0.31

                      • 1.74

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,420,990

                      • 0.21

                      • 1.65

                      • SPDR® S&P Biotech ETF

                      •  

                        1,372,289

                      • -1.92

                      • 1.39

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • PRIMECAP Management Company

                      •  

                        11,922,396

                      • -5.94%

                      • 13.88

                      • Fidelity Management and Research Company

                      •  

                        11,640,950

                      • -4.49%

                      • 13.55

                      • ClearBridge Advisors, LLC

                      •  

                        9,980,315

                      • +7.33%

                      • 11.62

                      • Vanguard Group, Inc.

                      •  

                        5,201,812

                      • -0.80%

                      • 6.06

                      • First Trust Advisors L.P.

                      •  

                        4,121,730

                      • +14.21%

                      • 4.80

                      • Sectoral Asset Management Inc

                      •  

                        3,218,276

                      • -11.19%

                      • 3.75

                      • BB Biotech AG

                      •  

                        3,165,816

                      • 0.00%

                      • 3.69

                      • Bellevue Asset Management AG

                      •  

                        3,165,816

                      • 0.00%

                      • 3.68

                      • BlackRock Fund Advisors

                      •  

                        2,933,416

                      • -7.92%

                      • 3.41

                      • State Street Corp

                      •  

                        2,535,747

                      • -2.91%

                      • 2.95

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The C...moreompany develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: IMGN853, IMGN289, and IMGN529. It’s IMGN853 product candidate is used for the treatment of ovarian cancer, endometrial cancer, and potentially other cancers that highly express folate receptor a, or FRa. It’s EGFR-targeting ADC, IMGN289, is used for the treatment of cancers that highly express EGFR which include squamous cell carcinoma of the head and neck, or SCCHN, and types of non-small cell lung cancer (NSCLC), including both squamous c...moreell and non-squamous cell NSCLCs. It’s IMGN529 ADC is used for the treatment of cancers that highly express CD37, such as non-Hodgkin lymphoma, or NHL, and chronic lymphocytic leukemia. The Company’s main competitors include Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. In addition to regulations in the U.S., the company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.lessless

                      Key People

                      Mr. Daniel M. Junius

                      CEO/Director/President

                      Mr. Stephen C. Mccluski

                      Chairman of the Board/Director

                      Mr. David Johnston

                      CFO/Executive VP/Chief Accounting Officer

                      Dr. John M. Lambert, Pd.D

                      Executive VP/Chief Scientific Officer

                      Dr. Charles Morris

                      Executive VP/Other Executive Officer

                      • Immunogen Inc

                      • 830 Winter Street

                      • Waltham, MA 02451

                      • USA.Map

                      • Phone: +1 781 895-0600

                      • Fax: +1 781 895-0611

                      • immunogen.com

                      Incorporated

                      1981

                      Employees

                      307

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: